New Nature Biotechnology findings report a more efficient in vivo cytosine base editing strategy using virus-like particles alongside uracil DNA glycosylase inhibition. The work focuses on overcoming low editing efficiencies that have limited cytosine base editing performance in living systems by strengthening the editing chemistry and improving functional delivery dynamics through VLP-based delivery.